SCM
DAWN

Superstring Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Superstring Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-349,679
Closed -$5.78M – 45
2024
Q1 		$5.78M Sell
349,679
-29,947
-8% -$448K 3.82% 8
2023
Q4 		$5.54M Buy
+379,626
New +$4.6M 3.96% 9

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Superstring Capital Management's DAWN Position: Q2 2024 in Review

Superstring Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2024, closing a stake of 349,679 shares — an estimated $5.78M sold.

Superstring Capital Management first reported a position in DAWN in Q4 2023 and held it in 2 quarters. The position peaked at $5.78M in Q1 2024. 156 funds tracked by Wall St. Rank hold DAWN as of Q2 2024.

  • Superstring Capital Management reported no remaining Day One Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Superstring Capital Management sold 349,679 Day One Biopharmaceuticals shares in Q2 2024, an estimated $5.78M.
  • Superstring Capital Management first reported a position in Day One Biopharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Superstring Capital Management's Day One Biopharmaceuticals position peaked at $5.78M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2024.

Based on Superstring Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.